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Abstract
Purpose To evaluate single photon emission computed
tomography (SPECT)/spiral computed tomography (CT)
fusion imaging for the diagnosis of bone metastasis in
patients with known cancer and to compare the diagnostic
efficacy of SPECT/CT fusion imaging with that of SPECT
alone and with SPECT + CT.
Materials and methods One hundred forty-one bone lesions
of 125 cancer patients (with nonspecific bone findings on
bone scintigraphy) were investigated in the study. SPECT,
CT, and SPECT/CT fusion images were acquired simulta-
neously. All images were interpreted independently by two
experienced nuclear medicine physicians. In cases of
discrepancy, consensus was obtained by a joint reading.
The final diagnosis was based on biopsy proof and
radiologic follow-up over at least 1 year.
Results The final diagnosis revealed 63 malignant bone
lesions and 78 benign lesions. The diagnostic sensitivity of
SPECT, SPECT + CT, and SPECT/CT fusion imaging for
malignant lesions was 82.5%, 93.7%, and 98.4%, respec-
tively. Specificity was 66.7%, 80.8%, and 93.6%, respec-
tively. Accuracy was 73.8%, 86.5%, and 95.7%,
respectively. The specificity and accuracy of SPECT/CT
fusion imaging for the diagnosis malignant bone lesions
were significantly higher than those of SPECT alone and of
SPECT + CT (P<0.05). Among 37 equivocal lesions
revealed with SPECT, the diagnostic accuracy of bone
lesions was 45.9% for SPECT + CT and 81.1% for SPECT/
CT fusion imaging (χ2=9.855, P=0.002). The numbers of
equivocal lesions were 37, 18, and 5 for SPECT,
SPECT + CT, and SPECT/CT fusion imaging, respectively,
and 29.7% (11/37), 27.8% (5/18), and 20.0% (1/5) of
lesions were confirmed to be malignant by radiologic
follow-up over at least 1 year.
Conclusions SPECT/spiral CT is particularly valuable for
the diagnosis of bone metastasis in patients with known
cancer by providing precise anatomic localization and
detailed morphologic characteristics.
Keywords Bone lesion . Single photon emission computed
tomography (SPECT) . Computed tomography (CT) .
Fusion imaging
Introduction
Bone scintigraphy (BS) and computed tomography (CT)
are commonly utilized means to detect bone metastases
and are essential for the accurate staging and initiation
of appropriate treatment [1, 2]. BS has merit for whole-
body detection and has extremely high sensitivity for
detecting bone metastases in some primary cancers,
because even slight (5–15%) changes in local bone
turnover can be detected [3]. However, the specificity of
BS is low [4], because it does not provide information
about the nature and composition of the lesion. Single
photon emission computed tomography (SPECT) can
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overcome some of the problems associated with over-
lapping structures and poor anatomic localization on
planar images [5], but this is often insufficient in affording
a reliable and confident diagnosis [6]. In contrast, CT has
the advantages of fine anatomical resolution and high
specificity, but its disadvantages include relatively low
sensitivity and a limited area of examination. Furthermore,
the diagnostic process involving conventional multiple
devices is time consuming, which can increase the
patient’s anxiety and delay diagnosis and therapy. An
integrated SPECT/CT system combines the functional
specificity of SPECT with the anatomical precision of
CT as a possible solution to this dilemma [7].
Recently, a few reports assessed the value of SPECT/
low-dose CT in the diagnosis of osseous metastases [8, 9],
but this technique yields low-resolution anatomic images
that might be insufficient for image interpretation [10].
SPECT/spiral CT can yield diagnostically sufficient CT
images to provide clinicians with thorough and accurate
diagnostic information, but few studies have evaluated the
value of SPECT/spiral CT. Thus, the aim of our study was
to investigate SPECT/spiral CT fusion imaging in the
diagnosis of bone metastasis in patients with known cancer




From January 2007 to August 2007, 456 consecutive
patients with histologically confirmed primary tumors
underwent BS. One hundred and forty two (31%) patients
showed at least one indeterminate lesion. In 131 patients, a
SPECT/CT scan was acquired; the remaining 11 subjects
underwent SPECT alone for logistic reasons. Six of the 131
patients withdrew. Finally, 141 bone lesions in 125 patients
(58 women and 67 men; mean age 58.46±12.73 years;
range 30–84 years) were investigated in the study. The
predominant cancers were of the lung and breast (Table 1).
Institutional Review Board approval was obtained, and
each patient signed an informed written consent form.
System design
The hybrid SPECT/CT system incorporates a SPECT
scanner and a six-detector-row CT scanner (Precedence;
Philips Medical Systems, Cleveland, OH, USA).The CT
bed was modified so that routine CT and SPECT scanning
could be performed without moving the patient, thus
reducing misregistration artifacts, because no change in
the patients’ positioning would be required between scans.
Bone scintigraphy
Whole-body planar imaging in the anterior and posterior
positions was performed 3 h after intravenous injection of
740 MBq (20 mCi) of technetium-99m methylene
diphosphonate (Tc-99m MDP). Scintigraphy was obtained
with a dual-head large-field-of-view gamma camera
equipped with a low-energy, high-resolution, parallel-hole
collimator.
SPECT/CT scan
On the basis of findings from planar BS, which showed
indeterminate foci, the patients underwent SPECT/CT
scanning. The CT scan was performed first, then the bed
was positioned so that the SPECT scan could be performed
immediately after the CT acquisition. The interval between
SPECT and CT was less than 3 min. Both SPECT and CT
were performed during tidal breathing, with the patient
lying in a stable supine position. The following spiral CT
acquisition parameters were used: 120 kV, 140 mA, 1.225
pitch, 512 pixel×512 pixel matrix, 6.0 mm×1.5 mm
collimation, 5 mm scan, 3 mm reconstruction. The SPECT
protocol was the following: 128 pixel×128 pixel matrix,
1.0 magnification factor, 360° acquisition, 180° opposed
configuration, 6° steps, 30 s per frame.
Image reconstruction and fusion
SPECT data were reconstructed according to an ordered
subset expectation maximization (OSEM) algorithm with
four iterations and eight subsets. Images were smoothed by
three-dimensional post-filtering. CT images were recon-
structed with a high-resolution reconstruction algorithm
(B80 kernel). SPECT and CT data were fused by Philips
Table 1 Types, incidences, and percentages of primary tumors among
the 125 patients
Type Number Percent
Lung cancer 48 38.4
Breast cancer 30 24.0
Prostate cancer 10 8.0
Gastrointestinal carcinoma 10 8.0
Esophageal carcinoma 7 5.6
Hepatocellular carcinoma 4 3.2
Endometrial cancer 3 2.4
Uterine cervix cancer 3 2.4
Lymphoma 3 2.4
Head and neck cancer 3 2.4
Renal cancer 2 1.6
Malignant melanoma 2 1.6
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Syntegra software. A workstation displayed SPECT, CT,
and fused images with different percentages of SPECT and
CT blending.
Image interpretation
All images were interpreted independently by two experi-
enced nuclear medicine physicians who were aware of the
primary tumor but unaware of the results of other
investigations, such as symptoms and abnormal laboratory
results. In cases of discrepancy, consensus was obtained by
a joint reading. The degree of agreement between the two
reviewers was measured with the kappa statistic. Kappa
values were 0.53 for SPECT images, 0.616 for
SPECT + CT images, and 0.728 for fused images.
The reporters had undergone formal CT training that
included earning 100 h of CT continuing medical education
credit and interpreting 500 CT cases under the supervision
of a board-certified diagnostic radiologist [11]. First, the
reviewers read the SPECT images. Second, 4 weeks later,
the observers interpreted the SPECT + CT images. Third, a
further 4 weeks later, the readers interpreted SPECT/CT
images. These images were presented in random order to
each of the readers at each session. Diagnosis for each
lesion was visually scored with a 3-point scale: 1, definitely
benign; 2, equivocal; 3, definitely malignant.
The final diagnosis was based on biopsy proof and
radiologic follow-up over at least 1 year, including BS, CT,
and magnetic resonance imaging. An increase in tumor size
and/or a change in tumor nature (i.e., lytic or sclerotic) was
considered to be malignant, whereas no change in size and/
or nature over at least 1 year were regarded as benign [12].
Statistical analysis
Sensitivity, specificity, and accuracy of SPECT, SPECT + CT,
and SPECT/CT fusion imaging were computed by SPSS 13.0
software (SPSS Inc, Chicago, IL, USA). Data were compared
with the χ2 test. Values of P<0.05 were considered to be
statistically significant.
Results
A total of 141 areas of abnormal radiotracer uptake were
depicted in 125 patients on planar scintigraphic images; 111
patients had a single lesion, 12 had two lesions, and two
had three lesions. After validation, 63 lesions proved to be
malignant (i.e., ten osteoblastic, 21 osteolytic, and 32
mixed lesions), and 78 proved to be benign (i.e., 50
osteophyte, 12 arthrosis, 11 fracture and five postoperative
change). The diagnostic sensitivity of malignant bone
disease with SPECT + CT and SPECT/CT fusion imaging
was similar (P=0.365), but the specificity (χ2=5.74, P=
0.017) and accuracy (χ2=7.418, P=0.006) of SPECT/CT
fusion imaging were significantly higher (Table 2). Fur-
thermore, the diagnostic sensitivity (χ2=9.21, P=0.002),
specificity (χ2=17.75, P=0), and accuracy (χ2=26.37,
P=0) of the SPECT/CT fusion imaging were significantly
higher than those of SPECT alone (Table 2).
Among 37 equivocal lesions revealed with SPECT, the
diagnostic accuracy of malignant lesions was 45.9% for
SPECT + CT and 81.1% for SPECT/CT fusion imaging
(χ2=9.855, P=0.002; Table 3). The diagnostic precision of
SPECT, SPECT + CT, and SPECT/CT fusion imaging
showed marked differences, depending on the anatomic
region. Specifically, equivocal findings located in the spine
or the ribs could be correctly classified by SPECT/CT
fusion imaging (Table 4). Of the equivocal lesions revealed
by SPECT, SPECT + CT, and SPECT/CT fusion imaging,
the ratios of malignancy were 29.7% (11/37), 27.8% (5/18),
and 20.0% (1/5), respectively (Table 5). Figures 1 and 2
provide examples of how SPECT/CT enabled the correct
Table 2 Values (in percent) of SPECT, SPECT + CT, and SPECT/CT
fusion imaging in the diagnosis of malignant lesions
Modality Sensitivity Specificity Accuracy
SPECT 82.5* 66.7* 73.8*
SPECT+CT 93.7 80.8* 86.5*
SPECT/CT 98.4 93.6 95.7
*P<0.05, vs SPECT/CT
Table 3 Diagnostic gain (in percent) of SPECT + CT and SPECT/CT
fusion imaging in 37 equivocal lesions of SPECT. Equivocal lesions
were considered as incorrect lesions (χ2=9.855, P= 0.002)
Modality Correct Equivocal Incorrect
SPECT + CT 45.9(17/37) 48.7(18/37) 5.4(2/37)
SPECT/CT 81.1(30/37) 13.5(5/37) 5.4(2/37)
Table 4 Anatomic regions exhibiting equivocal lesions on SPECT,
SPECT + CT, and SPECT/CT fusion imaging
Anatomic region SPECT SPECT+CT SPECT/CT
Skull 5 2 1
Axial skeleton 15 7 0
Pelvis 4 2 2
Extremities 1 1 1
Rib 12 6 1
Total 37 18 5
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interpretation of focally increased bone uptake in different
clinical situations.
Discussion
SPECT/CT fusion imaging data are beneficial for the
precise detection of morphologic abnormalities from un-
clear scintigraphic lesions, thus resulting in a reliable
diagnosis [13, 14]. The success of integrated SPECT/CT
fusion imaging has heralded a new era in medical imaging
in which image fusion is being increasingly accepted as
reliable and accurate for ensuring precise image co-
registration [15].
Our study showed that the diagnostic specificity and
accuracy of malignant bone lesions were significantly
higher with SPECT/CT fusion imaging than with SPECT
alone or with SPECT + CT (P<0.05). SPECT was
extremely sensitive for detecting the area of increased
tracer uptake, and it could guide interpreters to determine
morphologic abnormalities on corresponding CT images.
Thus, SPECT/CT fusion imaging not only improved the
efficiency of reading images and shortened the diagnostic
process [16], but it also prevented the interpreters from
missing small osteolytic or osteoblastic lesions. Side-by-
side readings of unregistered or poorly registered, separate-
ly acquired image depend on the reviewer’s memory and
the ability of the interpreter to re-orient the images. This
method is inadequate for small lesions [17].
In a study with a design that was similar to ours, Horger
et al. [9] assessed the benefit of hybrid imaging for 104
lesions of 47 patients with known cancer. The diagnostic
sensitivity of SPECT, SPECT + CT, and SPECT/CT fusion
imaging was 94%, 100%, and 98%, respectively. Specific-
ity was 19%, 68%, and 81%, respectively, and accuracy
was 36%, 74%, and 85%, respectively. The sensitivity of
SPECT/CT fusion imaging and SPECT + CT was nearly
the same, but the specificity of SPECT/CT fusion imaging
was significantly higher than that of SPECT + CT (P=
0.015). The diagnostic specificity and accuracy of SPECT,
SPECT + CT, and SPECT/CT fusion imaging in our study
were higher than those reported by Horger et al. [9], for
which there may be several possible reasons. First, a low-
dose CT scanner was used by Horger et al. [9], and the
lower resolution anatomic images (approximately 4 mm)
[10] limited detail. Although we had a six-detector-row CT
system, it may have yielded CT images of higher spatial
resolution (approximately 0.7 mm), which should have
depicted small anatomic structures and produced high
diagnostic accuracy. Second, the acquisition time of a low
performance CT system is slow (approximately 10 min),
which might have increased the chances of patient
movement, thus resulting in misregistration between the
emission and transmission data and reducing the overall
accuracy of the fusion process [18]. The acquisition time of
a spiral CT scanner is faster (<1 min), thus reducing
misregistration artifacts from patient positioning and
changes in gastrointestinal or urinary tract contents [19].
Third, Horger et al. [9] reported that the prevalence of
breast and lung cancer was 48.9% in 47 patients, and the
Table 5 Numbers and percentages of benign and malignant lesions
by follow-up within equivocal lesions revealed by SPECT,
SPECT + CT, and SPECT/CT fusion imaging
Modalities Benign Malignant Total
SPECT 26 (70.3%) 11 (29.7%) 37
SPECT + CT 13 (72.2%) 5 (27.8%) 18
SPECT/CT 4 (80.0%) 1 (20.0%) 5
Fig. 1 Images of a 66-year-old woman with lung cancer. a SPECT/
CT fusion image showing the increased area of activity in the
posterior part of the right seventh rib. b CT image showing destruction
of the posterior part of the right seventh rib. The final diagnosis was
bone metastasis. SPECT/CT sensitive for displaying increased tracer
uptake could guide interpreters to determine morphologic abnormal-
ities on corresponding CT images. Thus, SPECT/CT fusion imaging
accelerated workflow and helped the interpreters to avoid missing
small lesions
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prevalence of head and neck cancer was 17.0%. In our
series the former was 62.4% in 125 cases and the latter was
2.1%. Therefore, the different percentages of primary
tumors may have affected diagnostic specificity and
accuracy.
In our group, for 37 equivocal lesions on SPECT, the
diagnostic accuracy of SPECT/CT fusion imaging was
significantly higher than that of SPECT + CT (P=0.002),
which may have been the result of the following. First,
SPECT + CT might not have provided precise localization
to allow for conditions such as costovertebral arthritis and
vertebral osteomyelitis. Second, osteolysis was located
medially only a few millimeters from the facet joint in the
lamina, and the interpreters reviewing the SPECT + CT
images may have tended to misdiagnose the increased bone
metabolism as a degeneration of the facet [16, 20]. Third,
especially difficult was the differentiation of the bone island
from slightly sclerotic change (early sclerotic metastasis) on
Fig. 2 Images of a 64-year-old woman with breast cancer. a CT
image showing changes of hyperostosis and osteosclerosis in the L3
facet joint. b SPECT image showing that the activity is in the region
of the facet joint. c SPECT/CT fusion image showing that the
increased area of activity in the left part of L3 seen on the SPECT
image matches the site of hyperostosis and osteosclerosis in the facet
joint seen on the CT image. The final diagnosis was of degenerative
change
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SPECT + CT images. Fourth, metastatic foci representing
slight changes may have been overlooked on SPECT + CT
images which could be detected on fused images.
In our study, for equivocal findings from SPECT,
SPECT + CT, and SPECT/CT fusion imaging, the ratio of
malignancy was 29.7% (11/37), 27.8% (5/18), and 20.0%
(1/5), respectively, by follow-up. Clarification of the nature
of the indeterminate lesions was important, because the
differentiation between malignant and benign lesions is
very helpful for guiding patient care. Early diagnosis of
bone metastases could influence additional or intensified
treatment [21], which in turn may prolong survival and
improve quality of life. Early diagnosis of benign bone
lesions would exclude the need for chemotherapy or
radiotherapy, which would lessen the economic burden
and stress for patients. SPECT/CT enables a one-stop
approach to bone lesion characterization while shortening
the diagnostic process, improving patient care and reducing
patient anxiety.
Several limitations in our study should be noted. First, a
detailed bone histopathologic analysis (five patients) was
not feasible. We confirmed bone metastasis on the basis of
radiologic follow-up (120 patients). A small proportion of
bone metastases, such as in breast cancer, could remain
unchanged in appearance despite lack of therapy. Change in
a lesion (such as infection and aneurysmal bone cyst)
within 1 year does not prove that a lesion had been a
metastasis. Second, the patients at our hospital might not be
considered typical of other centers, and the findings might
be considered to be relatively institution-specific. Third, we
analyzed our data only on a lesion-by-lesion basis and not
on a per patient basis.
Multicenter, prospective studies will be needed to show
the specific clinical indications for, and the cost effective-
ness of, SPECT/CT fusion imaging. Further studies should
also compare the value of SPECT/CT with other modalities,
such as [18F]fluoro-2-deoxy-D-glucose positron emission
tomography/CT or whole-body magnetic resonance imag-
ing, in detecting osseous metastases [22–24].
Conclusions
SPECT/CT fusion imaging outperformed side-by-side
reading of SPECT + CT data. It is particularly valuable in
the diagnosis of bone metastasis in patients with known
cancer because of precise anatomic localization and
detailed CT morphologic characteristics of radiotracer
uptake.
Acknowledgements We thank BioMed Proofreading for assistance
in editing the manuscript. We also thank the technicians in nuclear
medicine for their enduring support during this study.
References
1. Chowdhury FU, Scarsbrook AF. The role of hybrid SPECT-CT in
oncology: current and emerging clinical applications. Clin Radiol.
2008;6:241–51.
2. Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis
of bone metastases. Q J Nucl Med. 2001;45:53–64.
3. Even-Sapir E. Imaging of malignant bone involvement by
morphologic, scintigraphic and hybrid modalities. J Nucl Med.
2005;46:1356–67.
4. Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro CJ.
Radionuclide bone imaging: an illustrative review. Radiographics.
2003;23:341–58.
5. Bushnell DL, Kahn D, Huston B, Bevering CG. Utility of SPECT
imaging for determination of vertebral metastases in patients with
known primary tumors. Skeletal Radiol. 1995;24:13–6.
6. Reinartz P, Schaffeldt J, Sabri O, et al. Benign versus malignant
osseous lesions in the lumbar vertebrae: differentiation by means
of bone SPET. Eur J Nucl Med. 2000;27:721–6.
7. Townsend DW. Dual-modality imaging: combining anatomy and
function. J Nucl Med. 2008;49:938–55.
8. Schillaci O, Danieli R, Manni C, Simonetti G. Is SPECT/CT with
a hybrid camera useful to improve scintigraphic imaging
interpretation? Nucl Med Commun. 2004;5:705–10.
9. Horger M, Eschmann SM, Pfannenberg C, et al. Evaluation of
combined transmission and emission tomography for classifi-
cation of skeletal lesions. AJR Am J Roentgenol. 2004;
183:655–61.
10. Horger M, Bares R. The role of single-photon emission computed
tomography/computed tomography in benign and malignant bone
disease. Semin Nucl Med. 2006;36:275–85.
11. Delbeke D, Edward RC, Guiberteau MJ, et al. Procedure guideline
for SPECT/CT imaging 1.0. J Nucl Med. 2006;47:1227–34.
12. Daisuke U, Shinya S, Masanori I, et al. Added value of SPECT/
CT fusion in assessing suspected bone metastasis: comparison
with scintigraphy alone and nonfused scintigraphy and CT.
Radiology. 2006;238:264–71.
13. Roarke MC, Nguyen BD, Pockaj BA. Applications of SPECT/
CT in nuclear radiology. AJR Am J Roentgenol. 2008;191:
W135–50.
14. Strobel K, Burger C, Seifert B, et al. Characterization of focal
bone lesions in the axial skeleton: performance of planar bone
scintigraphy compared with SPECT and SPECT fused with CT.
AJR Am J Roentgenol. 2007;188:W467–74.
15. Roach PJ, Schembri GP, Ho Shon IA, et al. SPECT/CT imaging
using a spiral CT scanner for anatomical localization: impact on
diagnostic accuracy and reporter confidence in clinical practice.
Nucl Med Commun. 2006;27:977–87.
16. Romer W, Nomayr A, Uder M, et al. SPECT-guided CT for
evaluating foci of increased bone metabolism classified as
indeterminate on SPECT in cancer patients. J Nucl Med.
2006;47:1102–6.
17. Keidar Z, Israel O, Krausz Y. SPECT/CT in tumor imaging:
technical aspects and clinical applications. Semin Nucl Med.
2003;33:205–18.
18. Ruf J, Lehmkuhl L, Bertram H, et al. Impact of SPECT and
integrated low-dose CT after radioiodine therapy on the manage-
ment of patients with thyroid carcinoma. Nucl Med Commun.
2004;25:1177–82.
19. Schillaci O. Hybrid SPECT/CT: a new era for SPECT imaging.
Eur J Nucl Med Mol Imaging. 2005;32:521–4.
20. Romer W, Beckmann MW, Forst R, Bautz W, Kuwert T.
SPECT/spiral-CT hybrid imaging in unclear foci of increased
bone metabolism: a case report. Rontgenpraxis. 2005;55:
234–7.
Skeletal Radiol
21. Pomeranz SJ, Pretorius HT, Ramsingh PS. Bone scintigraphy and
multimodality imaging in bone neoplasia: strategies for imaging in
the new health care climate. Semin Nucl Med. 1994;24:188–207.
22. Ghanem N, Uhl M, Brink I, et al. Diagnostic value of MRI in
comparison to scintigraphy, PET, MS-CT and PET/CT for the
detection of metastases of bone. Eur J Radiol. 2005;55:41–55.
23. Schmidt GP, Reiser MF, Baur-Melnyk AB. Whole-body imaging
of the musculoskeletal system: the value of MR imaging. Skeletal
Radiol. 2007;36:1109–19.
24. Tian R, Su M, Tian Y, et al. Dual-time point PET/CT with F-18
FDG for the differentiation of malignant and benign bone lesions.
Skeletal Radiol. 2009;38:451–8.
Skeletal Radiol
